Holen Sie sich die Stockscreener-App
5.855
0.09%
-0.005
Handel nachbörslich:
5.88
0.025
+0.43%
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Abeona Therapeutics: Q3 Earnings Snapshot - New Haven Register
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Abeona Therapeutics Reports Q3 2024 Financial Highlights - TipRanks
Abeona Therapeutics Inc (ABEO) Quarterly 10-Q Report - Quartzy
Abeona Therapeutics reports Q3 EPS (63c) vs. (48c) last year - TipRanks
Abeona Therapeutics expects cash to fund operations into 2026 - TipRanks
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Abeona's pz-cel BLA Gains FDA Acceptance; Sets April 2025 PDUFA Date | ABEO Stock News - StockTitan
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Abeona Therapeutics announces FDA acceptance of BLA resubmission of pz-cel - TipRanks
Abeona Therapeutics® Announces FDA Acceptance of BLA - GlobeNewswire
FDA Accepts Abeona's Gene Therapy BLA for Rare Skin Disease, Sets 2025 Review Date | ABEO Stock News - StockTitan
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Objective long/short (ABEO) Report - Stock Traders Daily
Rosalind Advisors Inc. Has $11.58 Million Stock Position in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
abrdn plc Raises Position in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics® Announces Participation in November Investor Conferences - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dystrophic Epidermolysis Bullosa Market Expected to Experience Major Growth by 2034, According to DelveInsight | Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen, Abeona - Barchart
HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Cantor Fitzgerald Reiterates “Overweight” Rating for Abeona Therapeutics (NASDAQ:ABEO) - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – October 30, 2024 - CGTLive™
Cantor Fitzgerald Reaffirms Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
ABEOAbeona Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Abeona Therapeutics resubmits biologics license application for pz-cel to FDA - MSN
Abeona Therapeutics resubmits FDA application for gene therapy - Investing.com
Abeona Therapeutics® Completes Pz-cel Biologics License - GlobeNewswire
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration - StockTitan
(ABEO) Investment Analysis - Stock Traders Daily
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... - Yahoo Finance
(ABEO) Technical Pivots with Risk Controls - Stock Traders Daily
Abeona Therapeutics Targets RDEB Market With Promising Pz-Cel Therapy (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Renaissance Technologies LLC - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Drop in Short Interest - Defense World
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 7.4% in September - MarketBeat
Where are the Opportunities in (ABEO) - Stock Traders Daily
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Bought by Bank of New York Mellon Corp - Defense World
Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt? - Simply Wall St
Simplify Asset Management Inc. Invests $1.73 Million in Abeona Therapeutics Inc (NASDAQ:ABEO) - MarketBeat
Simplify Asset Management Inc. Makes New $1.73 Million Investment in Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Investment Analysts’ Updated EPS Estimates for September 20th (ABEO, ACET, ACHC, ACN, ADMA, AGIO, ALGS, ANGO, AWK, CAPR) - Defense World
Abeona Therapeutics’ (ABEO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Decrease in Short Interest - Defense World
Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Down 6.3% in August - MarketBeat
Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Below 200 Day Moving Average of $5.49 - MarketBeat
Dystrophic Epidermolysis Bullosa Market Expected - openPR
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):